Eisai Cuts Outlook But Emerging Markets Strong
This article was originally published in PharmAsia News
Executive Summary
The main take-away from Eisai's nine-month results was the downward revision of its full-year financial guidance, with both generics and a slow uptake of new drugs taking their toll - but emerging markets provided a brighter picture.